DK1487790T3 - Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystallisering - Google Patents
Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystalliseringInfo
- Publication number
- DK1487790T3 DK1487790T3 DK03745203.4T DK03745203T DK1487790T3 DK 1487790 T3 DK1487790 T3 DK 1487790T3 DK 03745203 T DK03745203 T DK 03745203T DK 1487790 T3 DK1487790 T3 DK 1487790T3
- Authority
- DK
- Denmark
- Prior art keywords
- lasofoxifene
- recrystallization
- opening
- purified
- racemic
- Prior art date
Links
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 title 2
- 229960002367 lasofoxifene Drugs 0.000 title 2
- 238000000034 method Methods 0.000 title 1
- 238000001953 recrystallisation Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36887202P | 2002-03-28 | 2002-03-28 | |
| PCT/IB2003/001033 WO2003082814A1 (en) | 2002-03-28 | 2003-03-17 | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1487790T3 true DK1487790T3 (da) | 2010-05-10 |
Family
ID=28675551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03745203.4T DK1487790T3 (da) | 2002-03-28 | 2003-03-17 | Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystallisering |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6906202B2 (da) |
| EP (1) | EP1487790B1 (da) |
| JP (1) | JP4268055B2 (da) |
| KR (1) | KR100636953B1 (da) |
| CN (1) | CN1283625C (da) |
| AR (1) | AR039152A1 (da) |
| AT (1) | ATE459599T1 (da) |
| AU (1) | AU2003209603B2 (da) |
| BR (1) | BR0308758A (da) |
| CA (1) | CA2479924C (da) |
| DE (1) | DE60331527D1 (da) |
| DK (1) | DK1487790T3 (da) |
| ES (1) | ES2339936T3 (da) |
| HU (1) | HUP0500025A3 (da) |
| IL (2) | IL162929A0 (da) |
| MX (1) | MXPA04009259A (da) |
| PL (1) | PL372727A1 (da) |
| RS (1) | RS80604A (da) |
| RU (1) | RU2278861C2 (da) |
| TW (1) | TW200306974A (da) |
| WO (1) | WO2003082814A1 (da) |
| ZA (1) | ZA200405209B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2479924C (en) * | 2002-03-28 | 2008-07-15 | Pfizer Products Inc. | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
| CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
| CN102311406A (zh) * | 2010-06-29 | 2012-01-11 | 武汉启瑞药业有限公司 | 拉索昔芬中间体的制备方法 |
| CN110099680B (zh) | 2016-10-11 | 2021-02-05 | 杜克大学 | Er+乳腺癌的拉索昔芬治疗 |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| KR102412089B1 (ko) | 2021-09-13 | 2022-06-22 | 주식회사 세라수 | Dmts의 정제방법 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2025043004A1 (en) | 2023-08-21 | 2025-02-27 | Duke University | Treatment of solid cancer with lasofoxifene |
| KR102663941B1 (ko) | 2024-03-04 | 2024-05-08 | 주식회사 세라수 | Drometrizole trisiloxane(DMTS)의 제조방법 |
| WO2026096820A1 (en) | 2024-10-30 | 2026-05-07 | Sermonix Pharmaceuticals, Inc. | Neoadjuvant treatment of er+ breast cancer with lasofoxifene |
| WO2026095931A1 (en) | 2024-10-30 | 2026-05-07 | Sermonix Pharmaceuticals, Inc. | Neoadjuvant treatment of er+ breast cancer with lasofoxifene |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903111A (en) * | 1972-09-11 | 1975-09-02 | Sandoz Ltd | 4-{8 3-Phenyl-pyrrolidin-1-yl{9 -butyrophenone derivatives |
| US5326865A (en) * | 1990-06-08 | 1994-07-05 | Hercules Incorporated | Arylazo and poly(arylazo) dyes having at least one core radical selected from naphthyl or anthracyl and having at least one 2,3-dihydro-1,3-dialkyl perimidine substituent |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| EP0756205A3 (en) * | 1995-07-26 | 1998-10-14 | Eastman Kodak Company | Pattern transfer techniques for fabrication of lenslet arrays using specialized polyesters |
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| YU26700A (sh) | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| EP1086692A3 (en) * | 1999-07-28 | 2003-07-09 | Pfizer Products Inc. | Estrogen agonists and antagonists for multiple indications |
| US6180375B1 (en) | 1999-08-27 | 2001-01-30 | Pfizer Inc. | Microbial biotransformation |
| AP2003002900A0 (en) | 2001-05-01 | 2003-12-31 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
| CA2479924C (en) * | 2002-03-28 | 2008-07-15 | Pfizer Products Inc. | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
-
2003
- 2003-03-17 CA CA002479924A patent/CA2479924C/en not_active Expired - Fee Related
- 2003-03-17 CN CNB038031175A patent/CN1283625C/zh not_active Expired - Lifetime
- 2003-03-17 RS YUP-806/04A patent/RS80604A/sr unknown
- 2003-03-17 AU AU2003209603A patent/AU2003209603B2/en not_active Ceased
- 2003-03-17 IL IL16292903A patent/IL162929A0/xx unknown
- 2003-03-17 HU HU0500025A patent/HUP0500025A3/hu unknown
- 2003-03-17 PL PL03372727A patent/PL372727A1/xx not_active Application Discontinuation
- 2003-03-17 DK DK03745203.4T patent/DK1487790T3/da active
- 2003-03-17 KR KR1020047015249A patent/KR100636953B1/ko not_active Expired - Fee Related
- 2003-03-17 ES ES03745203T patent/ES2339936T3/es not_active Expired - Lifetime
- 2003-03-17 RU RU2004128931/04A patent/RU2278861C2/ru not_active IP Right Cessation
- 2003-03-17 DE DE60331527T patent/DE60331527D1/de not_active Expired - Lifetime
- 2003-03-17 MX MXPA04009259A patent/MXPA04009259A/es active IP Right Grant
- 2003-03-17 BR BR0308758-1A patent/BR0308758A/pt not_active IP Right Cessation
- 2003-03-17 EP EP03745203A patent/EP1487790B1/en not_active Expired - Lifetime
- 2003-03-17 JP JP2003580282A patent/JP4268055B2/ja not_active Expired - Fee Related
- 2003-03-17 AT AT03745203T patent/ATE459599T1/de not_active IP Right Cessation
- 2003-03-17 WO PCT/IB2003/001033 patent/WO2003082814A1/en not_active Ceased
- 2003-03-26 AR ARP030101058A patent/AR039152A1/es unknown
- 2003-03-26 US US10/397,654 patent/US6906202B2/en not_active Expired - Lifetime
- 2003-03-27 TW TW092106928A patent/TW200306974A/zh unknown
-
2004
- 2004-06-30 ZA ZA2004/05209A patent/ZA200405209B/en unknown
- 2004-07-08 IL IL162929A patent/IL162929A/en active IP Right Grant
-
2005
- 2005-03-28 US US11/092,240 patent/US7358374B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1644384T3 (da) | Fremgangsmåde og mellemprodukter til syntese af entecavir | |
| DK1657246T3 (da) | Fremgangsmåde til forbedring af renhed og udbytte af sucralose | |
| DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
| DK1587821T6 (da) | Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning | |
| DK2517706T3 (da) | Fremgangsmåder og forbindelser til produktion af dipeptidylpeptidase iv-inhibitorer og mellemprodukter deraf | |
| DK1271537T3 (da) | Fremgangsmåde og indretning til simplificering af adgangen til metadata | |
| DK1501508T3 (da) | Inhibitorer af histondeatylase | |
| DK1997512T3 (da) | Fremgangsmåder til behandling af TWEAK-relaterede tilstande | |
| DK1504126T3 (da) | Fremgangsmåde til regulering af genekspression | |
| DK1480524T3 (da) | Fremgangsmåde til isolering af lactoferrin | |
| DK1716115T3 (da) | Syntese af acyloxyalkylcarbamat-prodrug og mellemprodukter deraf | |
| DK1384849T3 (da) | Skinne til et jalousi og fremgangsmåde til fastgørelse af en skinne til et jalousi | |
| DK3385267T3 (da) | Syntese af boronestere og syreforbindelser | |
| DK1585630T3 (da) | Fremgangsmåde til ekstraktion af kontaktlinser | |
| DK1425270T3 (da) | Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer | |
| DK1470732T3 (da) | Fremskaffelse af lokaliseringsinformation | |
| DK1509990T3 (da) | Konfiguration og fremgangsmåde til beskyttelse af omformerorganer | |
| DK1539200T3 (da) | Fremgangsmåde til behandling af multipel sklerose | |
| DK1353923T3 (da) | Forbedret fremgangsmåde til syntese af carbapenem | |
| DK1432683T3 (da) | Hidtil ukendte krystallinske polymorfe former af lercanidipinhydrochlorid og fremgangsmåder til fremstilling heraf | |
| DK1478438T3 (da) | Fremgangsmåder og sammensætninger til behandling af astma | |
| DK1620058T3 (da) | Sammensætning til forbedring af kognition og hukommelse | |
| DK1568280T3 (da) | Fremgangsmåde til fremstilling af fermenteret mælk og fermenteret mælk | |
| DK1575941T3 (da) | Fremgangsmåde til fremstilling af (S)-pantoprazol | |
| DK1519928T3 (da) | Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner |